ArticleGut microbes2023
Gut microbiota regulates postprandial GLP-1 response via ileal bile acid-TGR5 signaling.
Article in Gut microbes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 82 citations in OpenAlex.
- Glucagon-like peptide-1: a critical link between gut microbiota dysbiosis and degenerative musculoskeletal diseases.Gut microbes · 2026Review
- A novel bile salt hydrolase-producingGut microbes · 2026Article
- The gut microbiome-bile acid-FXR interplay: a pivotal axis in metabolic and gastrointestinal diseases.Gut microbes · 2026Review
- Gut-Brain-Skin Axis: From Mechanistic Insights to Translational Applications in Neurocosmetics.Dermatology and therapy · 2026Review
- Targeting microbial bile salt hydrolase reprograms bile acid metabolism and ameliorates metabolic dysfunction-associated steatohepatitis in mice.Molecular metabolism · 2026Article
- Metabolic dysfunction-associated steatotic liver disease: pathogenic mechanisms and exercise-induced molecular adaptations.Lipids in health and disease · 2026Review
- Review
- Oral probiotic delivery-based therapeutic strategies for inflammatory bowel disease.Asian journal of pharmaceutical sciences · 2026Review
- Limosilactobacillus reuteri Alleviates Parkinson's Disease by Regulating CDCA Secretion.Probiotics and antimicrobial proteins · 2026Article
- Bile Acids and the Gut-X Axis: TCM-Mediated Systemic Protection and Therapeutic Opportunities for Multi-Organ Diseases.Metabolites · 2026Review
- GLP-1 agonists and the gut microbiome: A bidirectional relationship.British journal of clinical pharmacology · 2026Review
- GLP-1 and Parkinson's Disease: A Comprehensive Review of Biology, Mechanisms and Efficacy.Cells · 2026Review
- Distinct Gut Microbiota Signatures Characterize Glucoregulatory Effects of Prenatal Choline and Betaine in Wistar Rat Offspring.The Journal of nutrition · 2026Article
- Type 2 Diabetes Mellitus as a Multisystem Disease: From Insulin Resistance to Organ Crosstalk-A Narrative Review.Biomedicines · 2026Review
- GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease.International journal of molecular sciences · 2026Review
- New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.Nutrients · 2026Review
- Anti‑obesity Effects of Lactiplantibacillus plantarum ZNFL-1 by Modulating Gut Microbiota and Lipid Metabolism in High‑Fat Diet‑Induced Mice.Probiotics and antimicrobial proteins · 2026Article
- Global Trends in Bariatric Surgery for the Treatment of Metabolic Syndrome: A Bibliometric and Visualization Analysis.Obesity surgery · 2026Article
- Article
- Prognostic and Diagnostic Value of Serum Bile Acid Profiles in Pancreatic Cancer: a Retrospective Multicenter Cohort Study.Journal of gastrointestinal cancer · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota interacts with intestinal epithelial cells through microbial metabolites to regulate the release of gut hormones. We investigated whether the gut microbiota affects the postprandial glucagon-like peptide-1 (GLP-1) response using antibiotic-treated mice and germ-free mice. Gut microbiome depletion completely abolished postprandial GLP-1 response in the circulation and ileum in a lipid tolerance test. Microbiome depletion did not influence the GLP-1 secretory function of primary ileal cells in response to stimulators in vitro, but dramatically changed the postprandial dynamics of endogenous bile acids, particularly ω-muricholic acid (ωMCA) and hyocholic acid (HCA). The bile acid receptor Takeda G protein-coupled receptor 5 (TGR5) but not farnesoid X receptor (FXR), participated in the regulation of postprandial GLP-1 response in the circulation and ileum, and ωMCA or HCA stimulated GLP-1 secretion via TGR5. Finally, fecal microbiota transplantation or ωMCA and HCA supplementation restored postprandial GLP-1 response. In conclusion, gut microbiota is indispensable for maintaining the postprandial GLP-1 response specifically in the ileum, and bile acid (ωMCA and HCA)-TGR5 signaling is involved in this process. This study helps to understand the essential interplay between the gut microbiota and host in regulating postprandial GLP-1 response and opens the foundation for new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.